Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
Cancer Medicine · 2023
DOI: 10.1002/cam4.5750 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Cancer Medicine, 2023. Verfasst von Guo Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The efficacy and toxicity profiles for extensive‐stage small cell lung cancer (ES‐SCLC) are unclear. We aimed to address this gap through a Bayesian network meta‐analysis.
Methods
We performed network analysis from randomized controlled trials comparing these treatments: PD‐(L)1 inhibitor, CTLA‐4 inhibitor, CXCR inhibitor, PARP inhibitor, CDK inhibitor, chemotherapy, and their combinations. Pooled estimations of progression‐free survival, overall survival, objective response rate, and toxicity (systematic and specific) were conducted within the Bayesian framework.
Results
Twenty‐five trials involving 9 strategies were included. In terms of progression‐free survival and overall survival, PD‐(L)1 inhibitor combined with cisplatin/carboplatin (P) and etoposide (E) shown the acknowledged superiority than other treatments. The addition of CTLA‐4 inhibitor (ipilimumab) to EP had the highest response rate among these regimens, and the combination of chemotherapy (irinotecan) and cisplatin/carboplatin had the greatest probability of performing considerable systematic security. The secondary endpoint was specific adverse events, including vomiting, fatigue, thrombocytopenia, constipation, and decreased appetite; hence we depicted the specific toxicity profile of each regimen. In addition, we identified the differences between PD‐1 inhibitors and PD‐L1 inhibitors in prolonging overall survival time for the central nervous system (CNS)/liver metastases patients.
Conclusions
EP combined with PD‐(L)1 inhibitor followed by CTLA‐4 inhibitors or anti‐angiogenesis was the considerable treatment with considerable efficacy and safety for ES‐SCLC. Each treatment has a unique specific toxicity profile, which needs more attention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Guo Lin
Förderung
- Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Lin, G., Yao, Z., Kang, K., Wang, H., Luo, R., & Lu, Y. (2023). Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis. Cancer Medicine. https://doi.org/10.1002/cam4.5750
Vancouver
Lin G, Yao Z, Kang K, Wang H, Luo R, Lu Y. Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis. Cancer Medicine. 2023. doi:10.1002/cam4.5750
BibTeX
@article{Lin2023,
author = {Lin, Guo and Yao, Zhuoran and Kang, Kai and Wang, Hui and Luo, Ren and Lu, You},
title = {Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5750}
}
EUVIMED